Fig. 1

Neutralization of SARS-CoV-2 spike-pseudotyped lentivirus by sera of cancer patients and health care workers. a Comparison of 50% neutralization titer (NT₅₀) between cancer patients and health care workers (HCWs). Serially diluted sera were incubated with SARS-CoV-2 spike-pseudotyped lentivirus, followed by infection of HEK293T-ACE2 cells. The assay was carried out side by side for samples of healthy individuals and cancer patients to ensure valid comparisons. b Distribution ranges of NT₅₀ among four cancer patient groups. Note that 2 patients who had both CLL and breast cancer were included in each group. c Comparison of NT₅₀ between anti-B cell therapy and no anti-B cell therapy in cancer patients. Twenty-eight out of the 54 CLL patients and 19 out of the 45 NHL patients received anti-B cell therapy, with drugs including BTK inhibitors and anti-CD20 monoclonal antibodies. d Comparison of NT₅₀ between anti-PD1/PD-L1 and no anti-PD1/PD-L1 treatment in lung and breast cancer patients. e Comparison of NT₅₀ between Moderna and Pfizer vaccinees in health care workers (HCWs) and cancer patients. f Correlative analysis between NT₅₀ values and ages of cancer patients. g Comparison of NT₅₀ values between male and female cancer patients. h Correlative analysis between NT₅₀ values and days of collection after the second dose of vaccination. All correlative analyses were performed using Prism 5 (f and h). In all cases, NT₅₀ values indicated at top were calculated by taking the inverse of the 50% inhibitory dilution values obtained from least squares regression non-linear curve modeled with Prism. Statistical significance was determined by a one-tailed unpaired t-test. CLL: Chronic Lymphocytic Leukemia; NHL: Non-Hodgkin’s Lymphoma